CBD is popular for its anti-inflammatory effect by stimulating the endocannabinoid system. PEA has similar properties to CBD, but unlike CBD, it is produced by the body itself. PEA is a lipid amide that acts as an endogenous agonist known as the PPAR-alpha nuclear receptor. When this receptor is activated, PEA has a strong analgesic and anti-inflammatory effect, which can enhance the analgesic effect of endogenous cannabinoids such as AEA. AEA is an endogenous cannabinoid associated with the regulation of pain. CBD inhibits the fatty acid amide hydrolase (FAAH) that decomposes AEA. PEA is unique in that its structure is similar to AEA. Studies have shown that in combination with PEA can enhance the role of AEA and inhibit FAAH.
There are currently 21 clinical studies confirming the effectiveness of this ingredient. In a double-blind, placebo-controlled study recently published in the Journal of Inflammatory Pharmacology, 1,111 patients with mild to moderate osteoarthritis took 800 mg of PEA, 600 mg of PEA or placebo daily for 8 consecutive weeks. . The results showed that participants who took both doses of PEA had significantly lower pain and stiffness scores in the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) tests compared to placebo. At the same time, there was a significant decrease in the WOMAC index in subjects taking 600 mg of PEA. In the Pain Rating Scale, both groups of PEA subjects had significantly lower assessments of the most severe pain and mildest pain than placebo patients, and based on the Depression and Anxiety Stress Scale (DASS), the PEA subjects in both groups. Anxiety is also significantly lower than placebo.